Key clinical point: Circulating tumor cell count is an independent prognostic indicator of both progression-free and overall survival in patients with advanced non–small cell lung cancer.
Major finding: CTC counts of at least 5 cells per 7.5 mL were associated with reduced overall survival (hazard ratio, 2.75; P less than .001).
Study details: A retrospective analysis involving 550 patients with NSCLC from nine centers.
Disclosures: The investigators disclosed financial relationships with AstraZeneca, Novartis, Pfizer, and others.
Lindsay et al. ELCC 2019, Abstract 21O.